| For: | Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008; 14(32): 5098-5099 [PMID: 18763297 DOI: 10.3748/wjg.14.5098] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i32/5098.htm |
| Number | Citing Articles |
| 1 |
Željko Reiner. Management of patients with familial hypercholesterolaemia. Nature Reviews Cardiology 2015; 12(10) doi: 10.1038/nrcardio.2015.92
|
| 2 |
M V. Zykov. The problem of safety of lipid-lowering therapy. Kardiologiia 2019; 59(5S) doi: 10.18087/cardio.2505
|
| 3 |
Ahmad Wasfi Haddad, Mohammad N. Kloub, Wassim Abouzeid, Muhammad Hussain, Deema Haddad, Atheer Anwar, Qusai Al-maharmeh. Complicated Treatment Course of Severe Asymptomatic Hypertriglyceridemia: A Case Report and Literature Review. American Journal of Case Reports 2024; 25 doi: 10.12659/AJCR.943858
|
| 4 |
Rgia A. Othman, Semone B. Myrie, David Mymin, Louise S. Merkens, Jean-Baptiste Roullet, Robert D. Steiner, Peter J.H. Jones. Ezetimibe Reduces Plant Sterol Accumulation and Favorably Increases Platelet Count in Sitosterolemia. The Journal of Pediatrics 2015; 166(1) doi: 10.1016/j.jpeds.2014.08.069
|
| 5 |
Livija Šimičević, Lana Ganoci, Ena Karačić, Tamara Božina, Ivan Pećin, Vladimir Trkulja, Nada Božina. Liver enzyme elevations during statin–ezetimibe therapy in ABCG2 c.421C>A variant carriers: a case series and narrative review. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1840055
|
| 6 |
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky, Randal J. Thomas. Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 2009; 84(4) doi: 10.1016/S0025-6196(11)60545-4
|
| 7 |
Keshav Kumar Gupta, Shair Ali, Ranjodh Singh Sanghera. Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and Therapy 2019; 8(1) doi: 10.1007/s40119-018-0123-0
|
| 8 |
Yoonkyung Chang, Soojeong Eom, Minjeong Kim, Tae-Jin Song. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Medicina 2023; 59(4) doi: 10.3390/medicina59040776
|
| 9 |
Jenyfer M Fuentes-Mendoza, Marcio J Concepción-Zavaleta, Jeny J Mendoza-Godoy, Luis A Concepción-Urteaga, Carlos O Martínez-Gutiérrez, José Paz-Ibarra. Dyslipidemia in liver cirrhosis: Pathophysiology and emerging therapeutic approaches. World Journal of Hepatology 2026; 18(3): 115539 doi: 10.4254/wjh.v18.i3.115539
|
| 10 |
Dina Halegoua-De Marzio, Victor J. Navarro. Drug-Induced Liver Disease. 2013; doi: 10.1016/B978-0-12-387817-5.00029-7
|
| 11 |
Venice Du Pont, Richard K Plemper, Matthias J Schnell. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Current Opinion in Virology 2019; 35 doi: 10.1016/j.coviro.2018.12.009
|
| 12 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2009; 18(2) doi: 10.1002/pds.1645
|
| 13 |
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky, Randal J. Thomas. Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?. Mayo Clinic Proceedings 2009; 84(4) doi: 10.4065/84.4.353
|
| 14 |
Željko Reiner. Combined therapy in the treatment of dyslipidemia. Fundamental & Clinical Pharmacology 2010; 24(1) doi: 10.1111/j.1472-8206.2009.00764.x
|
| 15 |
Ryan C. Van Woerkom, Douglas G. Adler. Letter to the Editor. Journal of Clinical Lipidology 2010; 4(4) doi: 10.1016/j.jacl.2010.03.075
|
| 16 |
Michael Demyen, Kawtar Alkhalloufi, Nikolaos T. Pyrsopoulos. Lipid-Lowering Agents and Hepatotoxicity. Clinics in Liver Disease 2013; 17(4) doi: 10.1016/j.cld.2013.07.016
|
| 17 |
Retrospective Study on Hepatic Injury of Ezetimibe and Simvastatin Combination vs. Simvastatin. Journal of Korean Society of Health-System Pharmacists 2013; 30(6) doi: 10.32429/jkshp.2013.30.6.002
|
| 18 |
Tharsan Kanagalingam, Julieta Lazarte, David K.H. Wong, Robert A. Hegele. Liver Injury Associated With Ezetimibe Monotherapy. CJC Open 2021; 3(2) doi: 10.1016/j.cjco.2020.09.018
|
| 19 |
Silje Bergland Ellingsen, Elisabet Nordmo, Knut Tore Lappegård. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe. Clinical Medicine Insights: Case Reports 2017; 10 doi: 10.1177/1179547617731375
|
| 20 |
Fawaz Almutairi, Theresa C. Peterson, Michele Molinari, Mark J. Walsh, Ian Alwayn, Kevork M. Peltekian. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transplantation 2009; 15(5) doi: 10.1002/lt.21710
|
| 21 |
Nourhan K. Elsaeed, Refaat H. Abdelmoety, Ehab Elyamani, Lamiaa mohamed Mahmoud, Mahmoud Zidan, Lamiaa Mohammed Matter, Mohamed S. Imam, Fahad Mofareh Alosaimi, Faisal Sultan Alosaimi, Abdullah Abdulrahman Almehery, Aryam Abdullah Asiri, Refan A Maadi, Hoda Rabea, Mona A. Abdelrahman. Evaluation of relative safety and therapeutic efficacy of antihyperlipidemic drug regimens used alone or in combination in cardiovascular disease: randomized controlled study. Future Journal of Pharmaceutical Sciences 2026; 12(1) doi: 10.1186/s43094-026-01013-7
|